These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34079282)

  • 1. Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.
    Cheng Q; Wang J; Lv C; Xu J
    Onco Targets Ther; 2021; 14():3367-3372. PubMed ID: 34079282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases.
    Liu Y; Sun J; Tuo K
    Case Rep Oncol; 2023; 16(1):227-233. PubMed ID: 37069896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
    Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
    World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy.
    Wang N; Chen FL; Pan L; Teng Y; Wei XJ; Guo HG; Jiang XM; Huang L; Liu SC; Liang ZL; Li WY
    World J Clin Oncol; 2023 Dec; 14(12):606-619. PubMed ID: 38179402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report.
    Feng L; Gao X; Jiao Z; Wang Z; Min F
    Oncol Lett; 2023 Feb; 25(2):48. PubMed ID: 36644138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.
    Zhang Y; Li Y; Zhuang Z; Wang W; Wei C; Zhao D; Zhou D; Zhang W
    Front Oncol; 2021; 11():760405. PubMed ID: 35004280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma.
    Yadav BS
    World J Clin Oncol; 2024 Mar; 15(3):371-374. PubMed ID: 38576595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
    Wang L; Guan W; Peng X
    Front Oncol; 2021; 11():676792. PubMed ID: 33968786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.
    Bai SJ; He JX; Zheng YJ; Geng Y; Gao YN; Zhang CX; Wang YR; Qin LY; Wang WJ; Yang LH
    Ann Hematol; 2024 May; ():. PubMed ID: 38761184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
    Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
    Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
    Alsuhebany N; Pan C; Holovac E; Do B; McBride A
    Blood Lymphat Cancer; 2023; 13():67-76. PubMed ID: 38034984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.